# Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

> **NCT00868959** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 817 (actual)

## Conditions studied

- Bipolar Depression

## Interventions

- **DRUG:** lurasidone

## Key facts

- **NCT ID:** NCT00868959
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 817 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868959, "Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00868959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*